Heparin Impurity Screening
Heparin impurity screening and analysis in accordance with Good Manufacturing Practice (GMP) or Good Laboratory Practice (GLP) to USP standards
Instances of contaminants observed in heparin pharmaceutical products and some medical devices, such as certain catheter products have driven the need for robust analytical approaches to detect/identify and quantify these contaminants. To ensure the safety of heparin-containing products, it is important to test the heparin active pharmaceutical ingredient (API) in these products.
Our scientists provide GMP compliant screening of specified impurities in heparin active pharmaceutical ingredients for heparin suppliers and manufacturers by applying 1H nuclear magnetic resonance (NMR) spectroscopy and liquid chromatography (LC), providing a more robust and thorough approach in accordance with contemporary standards.
Intertek’s heparin analytical services are carried out to US FDA recommendations – Stage 1 and Stage 2 methodology - can rapidly and effectively screen for the presence of specific impurities which have been highlighted as a safety concern by the FDA and consequently revised by USP. We are capable of identifying sections A, B and C of the Heparin Monograph Stage 2.
It is recommended that both screening techniques be used for the heparin API prior to batch release. These analytical approaches can also be used for GMP compliant finished product quality control (QC) applications. Contact our experts for specific requirements, including testing via CE (Capillary electrophoresis) at one of our GMP pharmaceutical laboratories. Bringing quality and safety to life, we offer Total Quality Assurance expertise to help you to meet and exceed quality, safety and regulatory standards
Need help or have a question?
Intertek Pharmaceutical Services Manchester
P.O. Box 42
Manchester, M9 8ZS
For location use: M9 8GQ